BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 37095531)

  • 1. High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma.
    Lang M; Schmidt LS; Wilson KM; Ricketts CJ; Sourbier C; Vocke CD; Wei D; Crooks DR; Yang Y; Gibbs BK; Zhang X; Klumpp-Thomas C; Chen L; Guha R; Ferrer M; McKnight C; Itkin Z; Wangsa D; Wangsa D; James A; Difilippantonio S; Karim B; Morís F; Ried T; Merino MJ; Srinivasan R; Thomas CJ; Linehan WM
    J Exp Clin Cancer Res; 2023 Apr; 42(1):99. PubMed ID: 37095531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GPNMB expression identifies TSC1/2/mTOR-associated and MiT family translocation-driven renal neoplasms.
    Salles DC; Asrani K; Woo J; Vidotto T; Liu HB; Vidal I; Matoso A; Netto GJ; Argani P; Lotan TL
    J Pathol; 2022 Jun; 257(2):158-171. PubMed ID: 35072947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease.
    Baba M; Furuya M; Motoshima T; Lang M; Funasaki S; Ma W; Sun HW; Hasumi H; Huang Y; Kato I; Kadomatsu T; Satou Y; Morris N; Karim BO; Ileva L; Kalen JD; Wilan Krisna LA; Hasumi Y; Sugiyama A; Kurahashi R; Nishimoto K; Oyama M; Nagashima Y; Kuroda N; Araki K; Eto M; Yao M; Kamba T; Suda T; Oike Y; Schmidt LS; Linehan WM
    Mol Cancer Res; 2019 Aug; 17(8):1613-1626. PubMed ID: 31043488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma.
    Wang XM; Zhang Y; Mannan R; Skala SL; Rangaswamy R; Chinnaiyan A; Su F; Cao X; Zelenka-Wang S; McMurry L; Xiao H; Spratt DE; Sangoi AR; Shao L; Betz BL; Brown N; Tickoo SK; McKenney JK; Argani P; Gupta S; Reuter VE; Chinnaiyan AM; Dhanasekaran SM; Mehra R
    Mod Pathol; 2021 Aug; 34(8):1596-1607. PubMed ID: 33854184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma.
    Damayanti NP; Budka JA; Khella HWZ; Ferris MW; Ku SY; Kauffman E; Wood AC; Ahmed K; Chintala VN; Adelaiye-Ogala R; Elbanna M; Orillion A; Chintala S; Kao C; Linehan WM; Yousef GM; Hollenhorst PC; Pili R
    Clin Cancer Res; 2018 Dec; 24(23):5977-5989. PubMed ID: 30061365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel gene fusion of PRCC-MITF defines a new member of MiT family translocation renal cell carcinoma: clinicopathological analysis and detection of the gene fusion by RNA sequencing and FISH.
    Xia QY; Wang XT; Ye SB; Wang X; Li R; Shi SS; Fang R; Zhang RS; Ma HH; Lu ZF; Shen Q; Bao W; Zhou XJ; Rao Q
    Histopathology; 2018 Apr; 72(5):786-794. PubMed ID: 29148086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic utility of one-stop fusion gene panel to detect TFE3/TFEB gene rearrangement and amplification in renal cell carcinomas.
    Harada S; Caliò A; Janowski KM; Morlote D; Rodriguez Pena MD; Canete-Portillo S; Harbi D; DeFrank G; Magi-Galluzzi C; Netto GJ; Martignoni G; Mackinnon AC
    Mod Pathol; 2021 Nov; 34(11):2055-2063. PubMed ID: 34148064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights.
    Simonaggio A; Ambrosetti D; Verkarre V; Auvray M; Oudard S; Vano YA
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of neoplasms with MITF/MiT family translocations.
    Wei S; Testa JR; Argani P
    Histol Histopathol; 2022 Apr; 37(4):311-321. PubMed ID: 35107169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translocation carcinomas of the kidney.
    Argani P
    Genes Chromosomes Cancer; 2022 May; 61(5):219-227. PubMed ID: 34704642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiT/TFE Family Renal Cell Carcinoma.
    Tang J; Baba M
    Genes (Basel); 2023 Jan; 14(1):. PubMed ID: 36672892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NEAT1-TFE3 and KAT6A-TFE3 renal cell carcinomas, new members of MiT family translocation renal cell carcinoma.
    Pei J; Cooper H; Flieder DB; Talarchek JN; Al-Saleem T; Uzzo RG; Dulaimi E; Patchefsky AS; Testa JR; Wei S
    Mod Pathol; 2019 May; 32(5):710-716. PubMed ID: 30622287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas.
    Martignoni G; Pea M; Gobbo S; Brunelli M; Bonetti F; Segala D; Pan CC; Netto G; Doglioni C; Hes O; Argani P; Chilosi M
    Mod Pathol; 2009 Aug; 22(8):1016-22. PubMed ID: 19396149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service.
    Green WM; Yonescu R; Morsberger L; Morris K; Netto GJ; Epstein JI; Illei PB; Allaf M; Ladanyi M; Griffin CA; Argani P
    Am J Surg Pathol; 2013 Aug; 37(8):1150-63. PubMed ID: 23715164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiT family translocation renal cell carcinoma.
    Argani P
    Semin Diagn Pathol; 2015 Mar; 32(2):103-13. PubMed ID: 25758327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lessons from 801 clinical TFE3/TFEB fluorescence in situ hybridization assays performed on renal cell carcinoma suspicious for MiTF family aberrations.
    Wang XM; Shao L; Xiao H; Myers JL; Pantanowitz L; Skala SL; Udager AM; Vaishampayan U; Mannan R; Dhanasekaran SM; Chinnaiyan AM; Betz BL; Brown N; Mehra R
    Am J Clin Pathol; 2023 Dec; 160(6):549-554. PubMed ID: 37499055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
    Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
    Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiT family translocation renal cell carcinoma in an elderly male.
    Prachi ; Aiyer HM
    Indian J Pathol Microbiol; 2021; 64(3):553-555. PubMed ID: 34341271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiT Family Translocation-Associated Renal Cell Carcinoma: A Contemporary Update With Emphasis on Morphologic, Immunophenotypic, and Molecular Mimics.
    Magers MJ; Udager AM; Mehra R
    Arch Pathol Lab Med; 2015 Oct; 139(10):1224-33. PubMed ID: 26414466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The classification of pediatric and young adult renal cell carcinomas registered on the children's oncology group (COG) protocol AREN03B2 after focused genetic testing.
    Cajaiba MM; Dyer LM; Geller JI; Jennings LJ; George D; Kirschmann D; Rohan SM; Cost NG; Khanna G; Mullen EA; Dome JS; Fernandez CV; Perlman EJ
    Cancer; 2018 Aug; 124(16):3381-3389. PubMed ID: 29905933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.